Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single‐arm, exploratory phase II trial.
Saved in:
| Title: | Camrelizumab in combination with doxorubicin, cisplatin, ifosfamide, and methotrexate in neoadjuvant treatment of resectable osteosarcoma: A prospective, single‐arm, exploratory phase II trial. |
|---|---|
| Authors: | Tang, Qinglian1,2 (AUTHOR), Zhang, Xinke2,3 (AUTHOR), Zhu, Xiaojun1,2 (AUTHOR), Xu, Huaiyuan1,2 (AUTHOR), Song, Guohui1,2 (AUTHOR), Lu, Jinchang1,2 (AUTHOR), Wu, Hao1,2 (AUTHOR), Deng, Chuangzhong1,2 (AUTHOR), Ai, Fei2,4 (AUTHOR), Zhang, Yingchun2,3 (AUTHOR) zhangyingch@sysucc.org.cn, Wang, Jin1,2 (AUTHOR) wangjinbs@sysucc.org.cn |
| Source: | Cancer Medicine. Sep2024, Vol. 13 Issue 18, p1-8. 8p. |
| Database: | Academic Search Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 20457634 |
|---|---|
| DOI: | 10.1002/cam4.70206 |
